| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: claimed is application of inhibitor of cell cycle checkpoint kinase 1 (CHK1), representing some derivatives of N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrole[2,3-b]pyridine-3-yl), or N-(5-bromo-4-(3-(methylamino)piperidin-1-yl)-5-bromo-1H-pyrrole[2,3-b]pyridine-3-yl)nicotinamide, for amplification of DNA-damaging agent, with first dose of said inhibitor being introduced 1 day after DNA-damaging agent, and second dose - two days after DNA-damaging agent. n EFFECT: claimed compounds amplified effect of DNA-damaging agent irinotecan or gemcitabine on tumour cells. n 30 cl, 13 dwg, 8 tbl, 12 ex |